Innovation Pharmaceuticals Inc (IPIX)

[frrol]

I found it interesting that the Aspire agreement called out OM in the "BD" definition of three Brilacidin deal, and did not include IBD. This is telling. It doesn't rule out a deal for IBD, but it shows the company feels the immediate prospects, or industry interests they are perceiving, are best for that one indication, OM. That was disappointing to see.
So: not expecting buyout news or IBD deal anytime soon. Looking for OM deal and P results. (And B-OM BTD getting less likely.)